Home » GTx Submits Clinical Hold CRL for Its Phase II Clinical Study of Capesaris Secondary Hormonal Therapy of Advanced Prostate Cancer
GTx Submits Clinical Hold CRL for Its Phase II Clinical Study of Capesaris Secondary Hormonal Therapy of Advanced Prostate Cancer
GTx announced that it has submitted to the FDA a complete response to the FDA’s letter regarding the previously announced full clinical hold of its clinical trials evaluating Capesaris (GTx-758) for primary (first line hormonal) androgen deprivation therapy for advanced prostate cancer and secondary (second line) hormonal therapy.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May